Table 2.

Pharmacogenetics studies on anti-IL17 drugs. HLA: human leukocyte antigens, PASI: Psoriasis Area and Severity Index, IL: interleukin.

Reference	Drug	Genes Studied	Response	Number of Patients	Country	Weeks after Initiation of Treatment	Outcome Measure
Costanzo et al, 2018 [68]	Secukinumab	HLA-C	HLA-C*06:02 had no relation to response	434	Italy	16 and 24	PASI50, PASI75, PASI90, PASI100
Anzengruber et al, 2018 [70]	Secukinumab	HLA-C	HLA-C*06:02 had no relation to response	18	Switzerland	12	PASI50, PASI75, PASI90
Papini et al, 2019 [69]	Secukinumab	HLA-C	HLA-C*06:02 had no relation to response	434	Italy	1, 2, 3, 4, 8, 12, 16, 20, 24, 36, 48, 60 and 72	PASI75, PASI90, PASI100
Vugt et al, 2020 [71]	Secukinumab and ixekizumab	IL-17	No relation to response	134	The Netherlands, Belgium, Italy, Estonia	12 and 24	PASI75, PASI90